Novo Nordisk consensus stays robust, analysts see upside for shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 14:35.

Novo Nordisk A/S (DK0062498333) remains one of the most closely watched European healthcare names, with analysts continuing to highlight its exposure to the obesity trend and steady diabetes franchise growth according to recent consensus data on MarketScreener and other platforms. Large-cap peers such as Eli Lilly in the S&P 500 serve as a benchmark for many international investors following the stock.

Analyst consensus on Novo Nordisk

Across major broker surveys compiled on platforms such as MarketScreener, a majority of analysts currently rate Novo Nordisk shares at Buy or Outperform, with only a small minority sitting on Sell recommendations according to the latest consensus overview. The average 12-month price target in these compilations stands meaningfully above the present share price level, reflecting expectations for continued growth from obesity and diabetes therapies. In many cases, target price updates over the past months have trended higher as forecasts for GLP-1 demand have been revised upward by the Street.

Goldman Sachs maintains a positive stance on the broader obesity and metabolic disease space and regularly cites Novo Nordisk as a key beneficiary in thematic healthcare reports that discuss GLP-1 penetration rates and long-term market potential. Other institutions such as JPMorgan and UBS have also highlighted the company in sector notes as one of the central European large caps tied to structural healthcare spending trends. In these publications, analysts often emphasize Novo Nordisk's strong cash generation, high return on capital and disciplined capital allocation as fundamental supports for the equity story.

How the shares trade in Europe and the US

Novo Nordisk stock trades primarily on Nasdaq Copenhagen, where it is part of the OMX Copenhagen 25 index, and the company also has a large American depositary receipt listing on the New York Stock Exchange that broadens access for US-based investors. The dual listing structure increases liquidity and makes Novo Nordisk a regular component of global healthcare and ESG portfolios, according to institutional ownership statistics reported in exchange filings. Many analysts reference the ADR line when comparing valuation multiples with US peers such as Eli Lilly, AbbVie and other large-cap pharmaceutical groups.

In recent months, trading volumes on both Nasdaq Copenhagen and the NYSE have tended to pick up around earnings releases and around major sector news, including data presentations at diabetes and obesity conferences, as reported in market commentary pieces from outlets such as Reuters and Bloomberg. These reports often note that Novo Nordisk's market capitalization has placed it among the most valuable listed companies in Europe, which further increases its weight in index-linked products and exchange-traded funds. For many portfolio managers, shifts in the company's index weight can drive incremental demand as passive strategies rebalance positions around quarter-end dates.

What the company sells

Novo Nordisk generates most of its revenue from diabetes and obesity treatments, including GLP-1 products such as Ozempic and Wegovy, along with a broad range of insulin formulations and related devices. The company also has smaller franchises in rare disease therapies, including treatments for hemophilia and growth disorders that diversify its earnings base.

Where the stock trades today

On Nasdaq Copenhagen, Novo Nordisk shares most recently traded around levels that, when converted, place the company among the largest European healthcare stocks by market capitalization, while the NYSE ADR line reflects similar valuation metrics in US dollars based on the latest available price data.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.